Reata Pharmaceuticals Inc (was by Biogen Inc. (Nasdaq: BIIB) on 26/09/2023) (RETA) Event Aug. 08, 2022, 00:00 UTC (51% Neutral) Reata Pharmaceuticals, Inc. (RETA) Reports Net Loss for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 5:34 p.m. 🏢 Reata Pharmaceuticals Inc (was by Biogen Inc. (Nasdaq: BIIB) on 26/09/2023) (RETA) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-08-08 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-140.16M $-140.16M N/A +0.00% ➡️ Total Assets $735.02M $631.55M $103.47M +16.38% 📈 Stockholders' Equity $313.83M $-1.10B $1.41B +128.57% 📈 R&D Expense $74.95M $79.14M $-4.19M -5.29% 📈 Earningspersharebasic $-3.87 $-4.04 $0.17 +4.21% ➡️ Earningspersharediluted $-3.87 $-4.04 $0.17 +4.21% ➡️ 📈 Financial Trend Analysis 🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Reata Pharmaceuticals Inc (was by Biogen Inc. (Nasdaq: BIIB) on 26/09/2023) (RETA) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document